Updated: March 29, 2026
Cefepime Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett

Summarize with AI
The Cefepime shortage continues in 2026. Get the latest on supply status, costs, alternatives, and how to find this IV antibiotic in stock.
The Cefepime Shortage Isn't Over — Here's What You Need to Know
If you've been told your hospital or pharmacy can't get Cefepime, you're experiencing the impact of a drug shortage that has affected patients across the country. As of 2026, Cefepime injection remains on the ASHP Drug Shortage list, and supply continues to be inconsistent across healthcare facilities.
This article gives you the latest on where the Cefepime shortage stands, what's driving it, how much the drug costs, and what you can do to find it or get an alternative.
Is Cefepime Still in Shortage?
Yes. Cefepime injection has been listed as a current shortage by the American Society of Health-System Pharmacists (ASHP). B. Braun, one of the key manufacturers of Cefepime injection, has reported shortages due to manufacturing delays. Other manufacturers including Baxter, Apotex, and Hospira have also experienced intermittent supply disruptions.
The FDA is aware of the situation and is working with manufacturers to mitigate the shortage, but full resolution has not yet been achieved. Supply availability varies significantly by region, hospital system, and distributor relationships.
Why Is Cefepime Hard to Find?
The Cefepime shortage is part of a broader crisis in sterile injectable drug manufacturing. Several interconnected factors are at play:
Manufacturing Complexity
Cefepime must be produced in sterile, FDA-inspected facilities. Any contamination event, equipment breakdown, or failed inspection can halt production for extended periods. The specialized nature of injectable drug manufacturing means that these problems can't be quickly resolved.
Too Few Manufacturers
Only a handful of companies worldwide produce generic Cefepime injection. Unlike oral medications with dozens of generic competitors, the sterile injectable market has high barriers to entry — expensive facilities, complex regulatory requirements, and low profit margins that discourage new entrants.
Supply Chain Vulnerabilities
Raw material sourcing, international shipping, and regulatory processes across multiple countries all add fragility to the supply chain. The sterile injectable sector has been among the most shortage-prone segments of the pharmaceutical industry since 2010.
Growing Demand
As hospital admissions increase and antibiotic-resistant infections become more common, demand for broad-spectrum IV antibiotics like Cefepime continues to rise. This puts additional pressure on already-strained supply.
For a deeper dive into the causes, read: Why is Cefepime so hard to find?
How Much Does Cefepime Cost in 2026?
Cefepime is a generic medication, but that doesn't mean it's cheap — especially for injectable drugs. Here's what you can expect:
- Cash price (without insurance): Approximately $200 to $600+ per treatment course, depending on the dose, vial size, and number of doses needed
- With a discount card: Services like SingleCare have listed prices as low as $93 for 9 vials of 2g Cefepime
- With insurance: Most hospital and facility-based insurance plans cover Cefepime as a medically necessary IV antibiotic. Your out-of-pocket cost depends on your plan's deductible and copay structure.
For detailed cost-saving strategies, see: How to save money on Cefepime in 2026.
Are There New Options in 2026?
One notable development is Exblifep, an FDA-approved combination of Cefepime with Enmetazobactam — a new beta-lactamase inhibitor. Exblifep extends Cefepime's effectiveness against some resistant bacteria, particularly those producing certain extended-spectrum beta-lactamases (ESBLs).
However, Exblifep is a brand-name product and is significantly more expensive than generic Cefepime. It's primarily intended for resistant infections, not as a routine replacement. Your infectious disease specialist can determine if Exblifep is appropriate for your situation.
Traditional alternatives remain available and effective for many infections:
- Piperacillin/Tazobactam (Zosyn)
- Meropenem (Merrem)
- Ceftazidime (Fortaz)
- Imipenem/Cilastatin (Primaxin)
Read the full comparison: Alternatives to Cefepime if you can't fill your prescription.
How to Find Cefepime in Stock
Even during a shortage, Cefepime is available at some facilities. Here's how to improve your chances of finding it:
- Search on Medfinder — Check real-time availability at pharmacies and facilities near you.
- Call specialty infusion pharmacies — These pharmacies focus on IV medications and often maintain dedicated stock of critical injectables.
- Ask your hospital pharmacy — They'll have the most current information on supply and expected restocks.
- Contact independent pharmacies — They may source from different distributors and have access to inventory that chain pharmacies don't.
- Check back regularly — Supply changes daily during shortages. What's unavailable today might be in stock tomorrow.
For more detailed strategies, see: How to find Cefepime in stock near you.
Final Thoughts
The Cefepime shortage is a frustrating reality in 2026. It's part of a systemic problem in sterile injectable manufacturing that the healthcare industry and federal regulators are working to address — but solutions are slow.
In the meantime, the best thing you can do is stay informed, stay in communication with your healthcare team, and use tools like Medfinder to find what you need faster.
If you're a healthcare provider looking for resources, check out our provider-focused articles: Cefepime shortage: What providers need to know and How to help patients find Cefepime in stock.
Frequently Asked Questions
There is no confirmed end date for the Cefepime shortage as of early 2026. The ASHP and FDA continue to monitor the situation and work with manufacturers. Resolution depends on manufacturing facilities coming back online and increasing production capacity, which can take months.
The shortage affects the entire U.S. market, but the impact is uneven. Some hospital systems and regions may have adequate supply while others are severely affected. Availability depends on each facility's distributor relationships and inventory management. Checking Medfinder or calling local facilities is the best way to assess availability in your area.
Yes. If Cefepime is unavailable, your doctor can evaluate your infection and determine whether an alternative like Piperacillin/Tazobactam (Zosyn), Meropenem, or Ceftazidime is appropriate. The choice depends on the type of bacteria, your lab results, kidney function, and allergy history.
Yes, pediatric patients are also impacted. Cefepime is approved for children aged 2 months and older for certain infections, including febrile neutropenia. Hospitals with pediatric units typically prioritize critical-need patients, but availability remains a concern. Your pediatrician or pediatric infectious disease specialist can recommend alternatives if needed.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsRelated articles
29,483 have already found their meds with Medfinder.
Start your search today.

![Who Has Vyvanse in Stock Near You? Find It Today [2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1079f61f167dcbc2ed5f1da17a0dcb0b7166357e-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)



